Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I get the frustrations regarding the mgt miss steps. What I don't understand is why use expressions such as inflection point or success at End of phase 2 BOM Fda meeting would help the company develop their other assets. Or success in OM or Pruisol would open up enormous opportunities. Why tell shareholders that without something all but signed. I don't buy that this is OTC or mgt is just attempting to draw suitors. At some point, it is or isn't and shareholders should be informed.
Thinking now is a good time to take a position. Why is 10k delayed?
Frrol, why do you think the market doesn't believe B? Because of the small sample size on OM? Wondering about ABSSSI results re why market writes that off? Or B UP pictures. Just seems strange to me.
B has passed 2 phase2 trials and has shown some good results in a third indication and the odds of success are approaching lotto? I would say the odds are getting better. Dilution has occurred and Leo is pushing it to the wire, but seems to me a deal will be much better than a buyout of .22 per share. However, the maximum value to shareholders should be licensing deal as this will allow all indications of B to play out at some point.
Frrol, your opinion...if IPIX is successful at obtaining partnership and let's say the amount is sufficient to cover OM trials and allow for development of other aspects of pipeline, how much dilution can still happen by MFO?
Thank you Phantom Lord and others. Much appreciated.
I see it as a positive. That Dr B is in for the long haul.
Yes, thank you Burrhead1. Do you know if there a simple summary somewhere that shows a 2019 time in terms of trial report outs?
Anyone know where I can find a condensed summary of upcoming catalyst?
Agreed. I looked up the one from early May, and it doesn't have the same disclamer unless I missed it. So, likely taking advantage of previous knowledge.
Leo has definitely taken a hit because of way he handled P and some other things. And I can see why many doubt, but he did say a successful BOM end of Ph2 meeting would help advance other aspects of the pipeline.
Dear IPIX Shareholders,
In just a few short weeks, we will be convening our Brilacidin-Oral Mucositis End-of-Phase 2 regulatory meeting. Success here not only would help us to complete development of the drug, but also to advance other aspects of our clinical pipeline.
Frrol, I don't think heavy dilution is the route Leo is thinking. All publications hint to some type of deal. Either way, it will be good to have resolution.
That they completed toxicology work and are commencing a phase 1 with pill.
Merry Christmas to all. Special thanks to TheDane and Frrol for your posts along with some others. I think the next news we hear will concern Kevetrin. I doubt we'll get a new year blog...nothing new to add except if partnership is sign.
Anyone there? Thinking now would be a good time to add to position.
I go back to the Nov 8 update where Leo mentioned that "either or" successful FDA meeting on B or P success would open up enormous possibilities. In the same update he mentioned advancing partnering discussions.
So, either or. Combined with the Thanksgiving email to shareholders. Why do that if not confident of deal concluding either way.
I'm trying to understand what company value would look like with BOM, BIBD, BI&I, and BA&A.
I am amazed at the drop in price for some of the small companies I am following. I can understand IPIX in light of P update and the need for partner. However, the other companies I am follow are down similarly but they have cash well into 2020 and with big market opportunity.
Add...“A successful End-of-Phase 2 FDA meeting for our Brilacidin-Oral Mucositis asset, or positive results from our Phase 2b Prurisol trial in psoriasis—either outcome we believe would open up enormous possibilities for our shareholders,” said Leo Ehrlich
You don't think the thanksgiving wish alludes to this?
Do you think FDA had same concern for ABSSSI? That was allowed to proceed to ph3.
How many executives email their shareholders wishing Happy Thanksgiving? Cant tell me Leo doesn’t want success for us all. He may have gambled a bit with the balance sheet, but I believe that he is doing everything he can to minimize dilution.
Added some shares at today's level. Just think the market is trying to process bigger macro issued at moment.
Maximum value comes to mind. Seems to me that if worse comes to worse, they could sell B OM outright for enough to pay off P CRO and fund B UP and K further. To me maximum value is still at play here, and that will happen at FDA meeting. Unless P is resolved before then. Either or. Having said all that, I believe the market potential and real value of company and pipeline are much higher.
What we know:
End of Phase 2 meeting on B OM in Dec.
Prurisol Phase 2b results not yet known, pending invoice payments.
K bridging toxicology work for pill is evolving.
B patent expanding.
B IBD shows promise.
B ABSSSI successful Phase 2.
Low funds are causing delays and dilution.
Potential markets are large if drugs successful.
Partnering discussions ongoing.
What we don't know:
Results of Prurisol Phase 2b.
BTD status on B OM.
Status of non binding term sheet.
No BTD means all hope is gone? From last PR... A successful End-of-Phase 2 FDA meeting for our Brilacidin-Oral Mucositis asset, or positive results from our Phase 2b Prurisol trial in psoriasis—either outcome we believe would open up enormous possibilities for our shareholders.
Of course it's a risk, but with great reward if proves effective. Risk at a low cost. Also, 2 reputable institutions are interested in a pill form.
Does anyone have prior experience with a company not achieving BTD after applying? Just wondering if an explanation is given. I just can't comprehend why FDA would possibly reject. New approach to medicine, impressive results, low cost solution, easy delivery method, a medical condition that needs solutions...
Term Sheet?
The more I think about B and the FDA regarding BTD, the more I think they should provide more incentives for drugs that are lower cost yet add new value to patients. Maybe Fast Track designation is intended for this but something different needs to be done soon.
Perhaps they're just finding a CRO at this point, so as funds become available they can complete the toxicology study...or the cost is minimal to complete it vs the relative value of announcing something positive that may come from it. However, some info in the PR was new, and I'm glad they are being proactive. Just wish more clarification would be provided on P and B.
Why would Leo obtain more financing if a B Deal is not imminent?
Are new symbol shares able to be purchased today as MRKR?
Sorry, guess malarkey means nonsense or meaningless talk. My apologies.
In 244801 he accuses Dr B of deception and lies.
scottsmith Sunday, 10/14/18 09:43:06 AMRe: DesireToLearn post# 2447990Post # of 244852
You keep on believing the malarkey that Leo and Art put in the PRs and filings! That’ll go real well lol.
From Sept 20 PR by Dr B
“Near-term strategic clinical priorities remain: to work closely with the FDA and other regulatory authorities to align on the remaining development plan necessary for Brilacidin in Oral Mucositis; to analyze the Prurisol Phase 2b data in Psoriasis; and, as additional funding becomes available, to commence work on new product formulations.
Then latest PR..
These funds will be used to continue to advance the Company’s pipeline of first-in-class drug candidates: Brilacidin for Oral Mucositis, Kevetrin for Ovarian Cancer and Prurisol for Psoriasis.
This new financing serves to further bolster our balance sheet and gives us flexibility in working to meet our near-term goals..
If company spends money on P within next few weeks, then I see this as a very positive sign. To me, it would mean confidence in B deal. Dr B did mention P results as a near term item, implying somewhat that this funding is partially geared toward P.
A comparison between ALLO and TPIV is interesting to me. How did ALLO raise close to $300m and yet have a 3.1b market value? TPIV market value at 100m, how will pricing at MRKR opening work? Does someone set the initial price or does it start from where we're at?
If no one wants it now then why buy it at auction? Because they don't want to pay for true value? My guess is deal after FDA meeting.
Can someone explain why the DoD would be interested in funding the trial?
Does IBD being included count?